Biotech expert eyes Sangamo (SGMO)

---

by John McCamant, editor The Medical Technology Stock Letter

Sangamo BioSciences (SGMO) has been receiving the kind of news that biotech companies dream of, with multiple main-stream news outlets picking up the story that the company is developing what may be a “functional cure” for AIDS.

The treatments that SGMO is developing are exciting, and we see this stock going much higher this year and in subsequent years based on clinical progress.